scholarly journals Development of 5-Trifluoromethylpyrimidine Derivatives as Dual Inhibitors of EGFR and SRC for Cancer Therapy

Heterocycles ◽  
2022 ◽  
Vol 104 (3) ◽  
Author(s):  
Longjia Yan ◽  
Li Liu ◽  
Qin Wang ◽  
Nian Rao ◽  
Yi Le
Keyword(s):  
Cancer Therapy ◽  
Dual Inhibitors

Harmine-Based Dual Inhibitors Targeting Histone Deacetylase (HDAC) and DNA as a Promising Strategy for Cancer Therapy

2022 ◽  
pp. 105604
Author(s):  
Dehua Lu ◽  
Lailiang Qu ◽  
Cheng Wang ◽  
Heng Luo ◽  
Shang Li ◽  
...  
Keyword(s):  
Cancer Therapy ◽  
Histone Deacetylase ◽  
Promising Strategy ◽  
Dual Inhibitors

scholarly journals Identification of 3-amidoquinoline derivatives as PI3K/mTOR dual inhibitors with potential for cancer therapy

RSC Advances ◽  
2017 ◽  
Vol 7 (4) ◽  
pp. 2342-2350 ◽  
Author(s):  
Jiankang Zhang ◽  
Xiaodong Ma ◽  
Xiaoqing Lv ◽  
Ming Li ◽  
Yanmei Zhao ◽  
...  
Keyword(s):  
Cancer Therapy ◽  
Dual Inhibitors

A new series of 3-amidoquinoline derivatives were designed, synthesized and evaluated as PI3K/mTOR dual inhibitors.

scholarly journals Synthesis, computational docking and biological evaluation of celastrol derivatives as dual inhibitors of SERCA and P-glycoprotein in cancer therapy

2021 ◽  
pp. 113676
Author(s):  
Paolo Coghi ◽  
Jerome P.L. Ng ◽  
Onat Kadioglu ◽  
Betty Yuen Kwan Law ◽  
Alena Congling Qiu ◽  
...  
Keyword(s):  
Cancer Therapy ◽  
Biological Evaluation ◽  
Computational Docking ◽  
P Glycoprotein ◽  
Dual Inhibitors

Research progress of dual inhibitors targeting crosstalk between histone epigenetic modulators for cancer therapy

2021 ◽  
pp. 113588
Author(s):  
Ying-Chao Duan ◽  
Shao-Jie Zhang ◽  
Xiao-Jing Shi ◽  
Lin-Feng Jin ◽  
Tong Yu ◽  
...  
Keyword(s):  
Cancer Therapy ◽  
Research Progress ◽  
Dual Inhibitors

Discovery of novel hybrids of diaryl-1,2,4-triazoles and caffeic acid as dual inhibitors of cyclooxygenase-2 and 5-lipoxygenase for cancer therapy

2016 ◽  
Vol 108 ◽  
pp. 89-103 ◽  
Author(s):  
Hao Cai ◽  
Xiaojing Huang ◽  
Shengtao Xu ◽  
Hao Shen ◽  
Pengfei Zhang ◽  
...  
Keyword(s):  
Cancer Therapy ◽  
Caffeic Acid ◽  
Cyclooxygenase 2 ◽  
Dual Inhibitors

scholarly journals Discovery and Characterization of Dual Inhibitors of MDM2 and NFAT1 for Pancreatic Cancer Therapy

2018 ◽  
Vol 78 (19) ◽  
pp. 5656-5667 ◽  
Author(s):  
Wei Wang ◽  
Jiang-Jiang Qin ◽  
Sukesh Voruganti ◽  
Bhavitavya Nijampatnam ◽  
Sadanandan E. Velu ◽  
...  
Keyword(s):  
Pancreatic Cancer ◽  
Cancer Therapy ◽  
Dual Inhibitors ◽  
Pancreatic Cancer Therapy

scholarly journals Two Birds with One Stone: NFAT1-MDM2 Dual Inhibitors for Cancer Therapy

Cells ◽  
2020 ◽  
Vol 9 (5) ◽  
pp. 1176
Author(s):  
Wei Wang ◽  
Atif Zafar ◽  
Mehrdad Rajaei ◽  
Ruiwen Zhang
Keyword(s):  
Cancer Therapy ◽  
Cancer Cells ◽  
Anticancer Activities ◽  
Activated T Cells ◽  
Cancer Subtypes ◽  
Mdm2 Expression ◽  
Dual Inhibitors ◽  
And Function

The tumor suppressor p53 is believed to be the mostly studied molecule in modern biomedical research. Although p53 interacts with hundreds of molecules to exert its biological functions, there are only a few modulators regulating its expression and function, with murine double minute 2 (MDM2) playing a key role in this regard. MDM2 also contributes to malignant transformation and cancer development through p53-dependent and -independent mechanisms. There is an increasing interest in developing MDM2 inhibitors for cancer prevention and therapy. We recently demonstrated that the nuclear factor of activated T cells 1 (NFAT1) activates MDM2 expression. NFAT1 regulates several cellular functions in cancer cells, such as cell proliferation, migration, invasion, angiogenesis, and drug resistance. Both NFAT isoforms and MDM2 are activated and overexpressed in several cancer subtypes. In addition, a positive correlation exists between NFAT1 and MDM2 in tumor tissues. Our recent clinical study has demonstrated that high expression levels of NFAT1 and MDM2 are independent predictors of a poor prognosis in patients with hepatocellular carcinoma. Thus, inhibition of the NFAT1-MDM2 pathway appears to be a novel potential therapeutic strategy for cancer. In this review, we summarize the potential oncogenic roles of MDM2 and NFAT1 in cancer cells and discuss the efforts of discovery and the development of several newly identified MDM2 and NFAT1 inhibitors, focusing on their potent in vitro and in vivo anticancer activities. This review also highlights strategies and future directions, including the need to focus on the development of more specific and effective NFAT1-MDM2 dual inhibitors for cancer therapy.

Multifunctional metal–organic framework heterostructures for enhanced cancer therapy

2021 ◽  
Author(s):  
Jintong Liu ◽  
Jing Huang ◽  
Lei Zhang ◽  
Jianping Lei
Keyword(s):  
Cancer Therapy ◽  
General Principle ◽  
Biomedical Applications ◽  
Metal Organic Framework ◽  
Metal Organic ◽  
Functional Modulation ◽  
Organic Framework

We review the general principle of the design and functional modulation of nanoscaled MOF heterostructures, and biomedical applications in enhanced therapy.

Sign in / Sign up

Export Citation Format

Share Document